Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Journal article (8)
Language
- English (8)
Keywords
- United States (2)
- cardiovascular disease (2)
- epidemiology (2)
- ASE formula (1)
- African-americans (1)
- Amino acids (1)
- Chronic Kidney-disease (1)
- Chronic kidney disease (1)
- Diabetes mellitus (1)
- Diabetic-nephropathy (1)
- European Society (1)
- General-population (1)
- Glomerular-filtration-rate (1)
- Glycaemic control (1)
- Haemodialysis (1)
- Heart failure (1)
- Hemoglobin A1C (1)
- Homoarginine (1)
- Insulin therapy (1)
- KDIGO (1)
- Mortality (1)
- Oral antidiabetic drugs (1)
- Progression (1)
- Risk (1)
- Stage renal-disease (1)
- Sudden cardiac death (1)
- Teichholz formula (1)
- Variants (1)
- aldosterone (1)
- atherosclerosis risk (1)
- blood-glucose control (1)
- cardiovascular events (1)
- cardiovascular morbidity (1)
- cardiovascularm disease (1)
- chronic kidney-disease (1)
- coa reductase inhibitors (1)
- consensus conference (1)
- coronary-heart-disease (1)
- cortisol (1)
- deep-vein thrombosis (1)
- diabetes complications (1)
- diabetes mellitus type 2 (1)
- diabetic nephropathy (1)
- double-blind (1)
- echocardiography (1)
- end stage renal disease (1)
- genetics (1)
- genome-wide association (1)
- global outcomes (1)
- glomerular filtration rate (1)
- glomerular-filtration-rate (1)
- hemodialysis (1)
- high-dose atorvastatin (1)
- insufficiency (1)
- kidney disease (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lipid-lowering therapy (1)
- men born (1)
- mortality (1)
- myocardial-infarction (1)
- placebo-controlled trial (1)
- primary prevention (1)
- replacement therapy (1)
- risk factors (1)
- serum creatinine (1)
- stage renal-disease (1)
- sudden cardiac death (1)
Institute
- Medizinische Klinik und Poliklinik I (8) (remove)
Background: Left ventricular hypertrophy (LVH), defined by the left ventricular mass index (LVMI), is highly prevalent in hemodialysis patients and a strong independent predictor of cardiovascular events. Compared to cardiac magnetic resonance imaging (CMR), echocardiography tends to overestimate the LVMI. Here, we evaluate the diagnostic performance of transthoracic echocardiography (TTE) compared to CMR regarding the assessment of LVMI in hemodialysis patients.
Methods: TTR and CMR data for 95 hemodialysis patients who participated in the MiREnDa trial were analyzed. The LVMI was calculated by two-dimensional (2D) TTE-guided M-mode measurements employing the American Society of Echocardiography (ASE) and Teichholz (Th) formulas, which were compared to the reference method, CMR.
Results: LVH was present in 44% of patients based on LVMI measured by CMR. LVMI measured by echocardiography correlated moderately with CMR, ASE: r = 0.44 (0.34-0.62); Th: r = 0.44 (0.32-0.62). Compared to CMR, both echocardiographic formulas overestimated LVMI (mean increment LVMI (ASE-CMR): 19.5 +/- 19.48 g/m(2),p < 0.001; mean increment LVMI (Th-CMR): 15.9 +/- 15.89 g/m(2),p < 0.001). We found greater LVMI overestimation in patients with LVH using the ASE formula compared to the Th formula. Stratification of patients into CMR LVMI quartiles showed a continuous decrease in increment LVMI with increasing CMR LVMI quartiles for the Th formula (p < 0.001) but not for the ASE formula (p = 0.772). Bland-Altman analysis showed that the Th formula had a constant bias independent of LVMI. Both methods had good discrimination ability for the detection of LVH (ROC-AUC: 0.819 (0.737-0.901) and 0.808 (0.723-0.892) for Th and ASE, respectively).
Conclusions: The ASE and Th formulas overestimate LVMI in hemodialysis patients. However, the overestimation is less with the Th formula, particularly with increasing LVMI. The results suggest that the Th formula should be preferred for measurement of LVMI in chronic hemodialysis patients.